Shares of CG Oncology catapulted Monday after the biotech unveiled promising results for a J&J-rivaling bladder cancer ...

Pfizer’s sasanlimab, when used with standard of care, reduced the likelihood of disease recurrence or progression, death due ...

CG Oncology shares rose Monday after the company shared positive data from a study of its bladder-cancer treatment. The stock gained 39% to $31.10 in premarket trading.

Pfizer has linked its PD-1 inhibitor to a 32% reduction in the risk of disease-related events in a phase 3 bladder cancer ...

Pfizer announced that its experimental drug sasanlimab, when combined with BCG therapy, significantly improved event-free ...

(UroToday.com) The American Urological Association's 2025 Annual Meeting, between April 26 – 29, 2025 in Las Vegas, Nevada, was host to the Society of Urologic Oncology (SUO) Session. Dr. Bernard ...

Oncologists at AUA 2025 share promising data, including sasanlimab, cretostimogene grenadenorepvec, and TAR-200 in NMIBC.

With an FDA review underway, Johnson & Johnson is aiming to “fundamentally change” how bladder cancer is treated. | With an ...

The positive predictive value (PPV) for Bladder EpiCheck was 67.4%, with a negative predictive value (NPV) for both overall and HG disease of 99.6%. WLC demonstrated a PPV of 74%, an NPV of 96.3%, and ...

Johnson & Johnson (JNJ) posts promising Phase 2b trial results for its chemotherapy releasing system TAR-200 in bladder ...

Dr. Matthew Galsky highlights the impact of Imfinzi’s adjuvant approval for patients with muscle-invasive bladder cancer ...

The United States has seen progress in reducing certain cancer risks, as overall smoking rates remain on a decline.